HC Wainwright Reaffirms “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPHGet Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, May 28th.

Read Our Latest Report on Reviva Pharmaceuticals

Reviva Pharmaceuticals Stock Performance

RVPH opened at $1.17 on Thursday. Reviva Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $6.80. The firm’s fifty day moving average is $1.57 and its 200 day moving average is $3.07. The stock has a market cap of $32.67 million, a price-to-earnings ratio of -0.74 and a beta of -0.09.

Reviva Pharmaceuticals (NASDAQ:RVPHGet Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. On average, equities research analysts predict that Reviva Pharmaceuticals will post -0.98 earnings per share for the current year.

Institutional Trading of Reviva Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. bought a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth about $72,000. Vanguard Group Inc. increased its holdings in shares of Reviva Pharmaceuticals by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 1,001,836 shares of the company’s stock worth $3,787,000 after buying an additional 26,854 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in shares of Reviva Pharmaceuticals by 194.0% in the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after buying an additional 1,164,000 shares during the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

Recommended Stories

Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.